Canaccord lowered the firm’s price target on Voyager Therapeutics (VYGR) to $12 from $14 and keeps a Buy rating on the shares. The firm said they reported its 4Q24 results showing Operating expenses came in at $44.6M versus estimates of $43.0M, and collaboration revenue was $6.3M versus $10.0M estimate. Canaccord believes the delta in both was most likely driven by the timing of R&D activity, which can be difficult to predict.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VYGR:
- Voyager Therapeutics: Strong Buy Rating Backed by Strategic Partnerships and Promising Pipeline
- Voyager Therapeutics’ Earnings Call Highlights Promising Future
- Promising Developments and Strong Financials Drive Buy Rating for Voyager Therapeutics
- Voyager Therapeutics price target lowered to $10 from $12 at Wells Fargo
- Voyager Therapeutics Reports 2024 Financial Results and Progress